News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
Market source Earnings
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
* Dyadic International press release [https://seekingalpha.com/pr/20616496-dyadic-announces-second-quarter-2026-financial-results-accelerating-commercialization] (DYAI [https://seekingalpha.com/symbol/DYAI]): Q2 GAAP EPS of -$0.06 misses by $0.03. * Revenue of $0.96M (-1.0% Y/Y) misses by $0.67M. * R&D Expenses: Research and development expenses for the three months ended June 30, 2026, were $332,621, a decrease …
Dyadic International, Inc. announced a new development and commercial license agreement with a European biotechnology company to expand its non-animal dairy pipeline. This agreement leverages Dyadic's Dapibus precision fermentation platform for commercially relevant dairy proteins and enzymes, aiming to generate recurring revenue through strategic …
Dyadic International, Inc. (Nasdaq: DYAI) announced it will report its financial results for the quarter ended June 30, 2026, and host a conference call on Wednesday, August 12, 2026, at 5:00 p.m. Eastern Time. The call will provide a corporate update, and details for …
Dyadic (Nasdaq: DYAI) announced that it successfully developed stable C1 cell lines and produced two Scripps-designed Bundibugyo ebolavirus recombinant protein antigens in approximately 15 days after receiving plasmids. These C1-produced antigens have been delivered to Fondazione Biotecnopolo di Siena and Scripps Research for preclinical …
Dyadic International (NASDAQ:DYAI) recently saw its share price cross above its 50-day moving average, trading as high as $1.60 before settling around $1.30 on significant volume. Despite this upward movement, analyst sentiment is mixed, with a "Hold" consensus and an average price target of …
Dyadic International, Inc., a biotechnology company, has announced that it has regained compliance with Nasdaq listing rules and its common stock will continue to be listed and traded on The Nasdaq Capital Market. The company's CEO, Mark Emalfarb, stated that this resolution allows them …
This article provides comprehensive financial information for Dyadic International, Inc. (DYAI), including its current stock price, market performance, key statistics, and company overview. It highlights the company's biotechnology platforms for protein and enzyme production and its various collaborations in the healthcare sector. The overview …
Dyadic International, Inc. announced the expansion of its bio-industrial pipeline with a new proprietary industrial enzyme program focused on advanced cellulose processing. This initiative, building on the EN3ZYME™ launch, showcases the scalability and versatility of the Dapibus™ platform for developing tailored enzyme solutions. The …
Search by ticker symbol or company name and select a result to open its chart.